Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

A phase Ib/II, open-label, multictr trial w/ oral cMET inhibitor INC280 alone & combined with erlotinib vs platinum/pemetrexed in adult patients w/ EGFR mutated, cMET-amplified, locally advanced/metastatic NSCLC with acquired resistance to prior EGFR TKI


Collapse Overview 
Collapse sponsor award id
2015


Collapse Biography 

Collapse Time 
Collapse start date
2017-05-22

Collapse end date
2020-06-01